While the role of cAMP pathway is complicated in HD and other GPR52-mediated cascades cannot be excluded, the fact that targeting GPR52 by genetic deletion or knockdown remarkably lessens mHTT levels and improves HD-related defects in multiple HD models is sufficiently compelling to justify GPR52 as a promising HD target. This evidence concerns the gene GPR52 and Huntington disease.